Opendata, web and dolomites

HominAb SIGNED

Discovering novel antibodies derived from the human body itself to treat neurodegenerative diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "HominAb" data sheet

The following table provides information about the project.

Coordinator
MABYLON AG 

Organization address
address: WAGISTRASSE 14
city: SCHLIEREN
postcode: 8952
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MABYLON AG CH (SCHLIEREN) coordinator 50˙000.00

Map

 Project objective

Neurodegenerative diseases are one of the disease fields with the highest unmet need. Decades of research have been invested in finding cures, however almost none have been successful. Antibodies have great therapeutic potential to treat these diseases as they are broadly applicable to specifically target different aspects of disease-causing processes. However, most of current non-human antibodies are limited by side-effects and a lack of specificity. Human-derived antibodies, derived from human blood samples, provide a solution for these limitations. They are naturally designed by the human immune system to fight toxic moieties with higher efficacy and specificity and are expected to have lower side-effects when compared to antibodies of non-human origin. However a large amount of blood samples is required to identify the rarest and most specific antibodies.

Mabylon is a biotechnology company that capitalizes on the human body’s own protective capability to generate antibodies against human disease. Mabylon’s unique screening platform allows identification of a “needle in the haystack” and develop fully human antibodies for diseases with high unmet medical need in the field of allergies and neurodegenerative diseases. Mabylon is currently developing several antibodies including an antibody for TDP-43, a toxic protein associated with diseases progression in ALS and FTD. ALS as a potential initial market could generate €110M in licensing revenue in 2021-2025 and €170M in royalties (5%) from 2026-2030. In addition, platform expansion towards other indications addresses a total neurodegenerative drug market worth €40B by 2022.

In the HominAb project, we will investigate our market positioning, the commercial landscape, preclinical development and licensing strategy in order to enable successful commercial maturation of our platform for neurodegenerative diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOMINAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOMINAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More